Navigation Links
Anti Atherosclerosis Therapies Linked to Leukemia

Scientists studying inflammation and atherosclerosis have recently seen a convergence of their respective fields. Another recent discovery made during the study// of anti atherosclerosis therapies was a tendancy towards development of a dangerous blood cancer known as hronic myelogenous leukemia, or CML.

Inflammation is an aspect of the immune response to injury and disease; atherosclerosis, with its characteristic lesions in the blood vessel walls, underlies most cardiovascular disease, including heart attacks and strokes.

Scientists at The Wistar Institute pursuing a promising new immune-system target for anti-atherosclerosis therapies discovered an unwanted potential side effect of any such therapies is a dangerous blood cancer called chronic myelogenous leukemia, or CML. More positively, the CML seen in the genetic strain of mice used in the study closely mimics human CML, so that the mice offer a new model for studying CML, opening the door for researchers to better understand that disease. The Wistar team's results are featured on the cover of the current issue of the Journal of Experimental Medicine, published October 30.

The Wistar scientists initiated their experiments to build on a series of findings that had suggested that blocking certain enzymes called lipoxygenases could inhibit the kind of chronic inflammation in the blood vessel walls that drives the atherosclerotic process. Even better, blocking these enzymes seemed only to affect one type of immune cell, the macrophage, and to interfere only with its role in chronic inflammation. The acute response of the macrophages to infectious agents like bacteria, critical for protection against disease, remained unfettered.

"We and others had hoped that blocking this enzyme would safely slow or stop certain chronic inflammatory responses that have been linked to atherosclerosis," says Ellen Puré, Ph.D., a professor in the Molecular and Cellular Oncogenesis and Immu nology programs at Wistar and senior author on the study. "Now we know that if we go that route, we may also unwittingly be promoting leukemia."

To better understand the details of this inflammatory process as it unfolds in atherosclerosis, the Wistar researchers worked with a strain of experimental mice lacking the gene for a specific pivotal lipoxygenase enzyme. They then crossed these mice with other strains of mice genetically prone to atherosclerosis. Would the resulting mice without the lipoxygenase enzyme be protected from developing atherosclerosis, or would their genetic susceptibility to atherosclerosis win out? Either way, precisely what mechanisms were at work in the vessel walls?

Focused as they were on the atherosclerotic process in the blood vessel walls, the researchers nearly overlooked a significant change taking place in another part of the body: To their surprise, they noticed that the spleens of the mice lacking lipoxygenase became enlarged, dramatically so in some cases. In 15 percent of the mice, the spleens grew 5 to 10 times their normal size at the end of a year.

"As immunologists, we couldn't ignore this," Puré says. "The spleen is an important organ of the immune system."

Exploring their observation, the scientists ascertained that the spleens of all of the mice in the experiments were somewhat enlarged, swollen with cells called granulocytes and macrophages, members of a family of immune cells called myeloid cells. The majority of mice were seen to have myeloid proliferative disease, a precursor to CML. And 15 percent of the mice had full-blown leukemias.

"The enzyme we were looking at is expressed in the progenitor cells in the bone marrow that give rise to all the different types of cells in one branch of the immune system," Puré notes. "So perhaps we shouldn't have been shocked to see that it had an effect on these cells to remove the enzyme from the system."

The silve r lining in the situation, Puré says, is that the strain of mice used in their study may be the best model for human CML yet found. The subset of the mice with myeloid proliferative disease closely mimic the asymptomatic early stages of CML, while the 15 percent with clear CML model the crisis, or "blast," stage of the disease.



Source-Eurekalert
LA
'"/>




Related medicine news :

1. Increase Cereal Fibre To Combat Atherosclerosis
2. Link Established Between Atherosclerosis and Air Pollution
3. Vegetarian Diet Prevents the Development of Atherosclerosis
4. Atherosclerosis and its Mechanics
5. Mothers Healthy Diet Protects Baby from Developing Atherosclerosis
6. Reducing the Risk of Protease Inhibitor-Related Atherosclerosis
7. Early Onset of Atherosclerosis Reported in Obese Children
8. Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis
9. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
10. Preventive Therapies Found to be More Effective in Managing Migraines
11. Ayurvedic Therapies Cashing In On Medical Tourism
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... 18, 2017 , ... Moore Insurance, a Houston area agency ... is launching a regional charity effort to provide publicity assistance and generate donations ... Tumor Foundation (PBTF) has raised nearly $30 million in donations that has been ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates ... residential and commercial clients in the greater Houston region, is helping locally recognized ... the fight against cancer. , Founded by Tony and Amber Bender after losing ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become a ... conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
(Date:8/18/2017)... ... 18, 2017 , ... Inc. magazine has ranked American Specialty Health, Incorporated (ASH) ... nation's fastest-growing private companies. This marks the eighth time in the last nine years ... year’s ranking reflects ASH’s 76 percent overall revenue growth from 2013 ($239 million) through ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about saving the ... Diane is from Southwest Nebraska where she was raised on a farm. As ... story is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ have always ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short ... to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology: